Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire E Wainwright

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|May 27, 2026
Multiple defects in macrophage antibacterial responses support intracellular survival of <i><i>Mycobacterium</i> abscessus</i> in cystic fibrosisAbdullah A Tarique, Stefan Emming, Dean Kelk, et al.
Clinical Chemistry|August 19, 2007
Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patientsBrendan J McMorran, Severine A Ouvry Patat, John B Carlin, et al.
American Journal of Respiratory and Critical Care Medicine|March 12, 2025
Infection by Clonally Related <i>Mycobacterium abscessus</i> Isolates: The Role of Drinking WaterRachel M Thomson, Nicole Wheeler, Rebecca E Stockwell, et al.
The Lancet. Respiratory Medicine|December 23, 2021
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trialSivagurunathan Sutharsan, Edward F McKone, Damian G Downey, et al.
The New England Journal of Medicine|November 4, 2011
A CFTR potentiator in patients with cystic fibrosis and the G551D mutationBonnie W Ramsey, Jane Davies, N Gerard McElvaney, et al.
Thorax|January 28, 2021
Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in AustraliaRoxanne Strachan, Nusrat Homaira, Sean Beggs, et al.
The New England Journal of Medicine|May 19, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey, et al.
The Lancet. Respiratory Medicine|February 13, 2021
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension studyPatrick A Flume, Reta Fischer Biner, Damian G Downey, et al.
Annals of the American Thoracic Society|September 8, 2025
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach StudyPedro Miranda Afonso, Grace C Zhou, Weiji Su, et al.
Pediatric Pulmonology|September 10, 2008
Safety of bronchoalveolar lavage in young children with cystic fibrosisClaire E Wainwright, Keith Grimwood, John B Carlin, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Proceedings of the National Academy of Sciences of the United States of America|May 27, 2026
Multiple defects in macrophage antibacterial responses support intracellular survival of <i><i>Mycobacterium</i> abscessus</i> in cystic fibrosisAbdullah A Tarique, Stefan Emming, Dean Kelk, et al.
Clinical Chemistry|August 19, 2007
Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patientsBrendan J McMorran, Severine A Ouvry Patat, John B Carlin, et al.
American Journal of Respiratory and Critical Care Medicine|March 12, 2025
Infection by Clonally Related <i>Mycobacterium abscessus</i> Isolates: The Role of Drinking WaterRachel M Thomson, Nicole Wheeler, Rebecca E Stockwell, et al.
The Lancet. Respiratory Medicine|December 23, 2021
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trialSivagurunathan Sutharsan, Edward F McKone, Damian G Downey, et al.
The New England Journal of Medicine|November 4, 2011
A CFTR potentiator in patients with cystic fibrosis and the G551D mutationBonnie W Ramsey, Jane Davies, N Gerard McElvaney, et al.
Thorax|January 28, 2021
Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in AustraliaRoxanne Strachan, Nusrat Homaira, Sean Beggs, et al.
The New England Journal of Medicine|May 19, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey, et al.
The Lancet. Respiratory Medicine|February 13, 2021
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension studyPatrick A Flume, Reta Fischer Biner, Damian G Downey, et al.
Annals of the American Thoracic Society|September 8, 2025
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach StudyPedro Miranda Afonso, Grace C Zhou, Weiji Su, et al.
Pediatric Pulmonology|September 10, 2008
Safety of bronchoalveolar lavage in young children with cystic fibrosisClaire E Wainwright, Keith Grimwood, John B Carlin, et al.
Pageof 10